title: Extremely late wound dehiscence following bevazicumab treatment in a long term survival glioblastoma patient.
authors.affiliation: Neurosurgery Department, Beilinson Hospital, Rabin Medical Center, Petah Tiqva 49100, Israel. Electronic address: yossilaviv@gmail.com.
authors.forename: Yosef
authors.initials: Y
authors.lastname: Laviv
authors.affiliation: Neurosurgery Department, Beilinson Hospital, Rabin Medical Center, Petah Tiqva 49100, Israel. Electronic address: zrappaport@clalit.org.il.
authors.forename: Zvi Harry
authors.initials: ZH
authors.lastname: Rappaport
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D003646:Debridement; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus; D008875:Middle Aged; D011183:Postoperative Complications / Q000473:pathology; D013524:Surgical Flaps / Q000473:pathology / Q000601:surgery; D013529:Surgical Wound Dehiscence / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D017741:Survivors
chemical_list: D000900:Anti-Bacterial Agents; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Bevacizumab; Craniotomy; Glioblastoma; Wound dehiscence